Collectively, these pleiotropic effects—including glucose lowering, cardiovascular risk reduction, renoprotection, modest weight loss, blood pressure lowering, and a low risk of hypoglycemia—position SGLT2 inhibitors uniquely for the management of T2DM and its comorbidities. This evidence concerns the gene SLC5A2 and Hypoglycemia.